What is the price target for RVLP stock?
9 analysts have analysed RVLP and the average price target is 3.21 USD. This implies a price increase of 11293.62% is expected in the next year compared to the current price of 0.0282.
RVL PHARMACEUTICALS PLC (RVLP) Forecast, Price Target & Analyst Ratings
NASDAQ:RVLP • IE00BF2HDL56
Current stock price
0.0282 USD
-0.01 (-32.05%)
At close:
0.0223 USD
-0.01 (-20.92%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for RVL PHARMACEUTICALS PLC (RVLP).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- Nov 8, 2023
- Period
- Q3 / 2023
- EPS Estimate
- -$0.09
- Revenue Estimate
- 6.728M
Price Target Details & History
Consensus Price Target and Range
Mean target
$3.21
Upside
+ 11,293.62%
From current price of $0.03 to mean target of $3.21, Based on 9 analyst forecasts
Low
$1.62
Median
$2.55
High
$6.30
Price Target Revisions
1 Month
15.81%
3 Months
-1.56%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for RVLP. The average price target is 3.21 USD. This implies a price increase of 11293.62% is expected in the next year compared to the current price of 0.0282.
The average price target has been revised downward by 1.56% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.22%
RVLP was analyzed by 9 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about RVLP.
In the previous month the buy percentage consensus was at a similar level.
RVLP was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-08-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-01 | Barclays | Maintains | Overweight |
| 2023-03-21 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-10-25 | Barclays | Maintains | Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- Nov 8, 2023
- Period
- Q3 / 2023
- EPS Estimate
- -$0.09
- Revenue Estimate
- 6.728M
- Revenue Q2Q
- -32.87%
- EPS Q2Q
- 43.47%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-51.29%
EPS (1 Month)
0.00%
EPS (3 Months)
4.04%
Next Earnings Summary
RVLP is expected to report earnings on 11/8/2023. The consensus EPS estimate for the next earnings is -0.09 USD and the consensus revenue estimate is 6.73M USD.
The next earnings revenue estimate has been revised downward by 51.29% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 177.884M -25.89% | 17.501M -90.16% | 49.721M 184.10% | 38.023M -23.53% | 54.887M 44.35% | 77.164M 40.59% | 174.93M 126.70% | 231.03M 32.07% | 288.46M 24.86% | 347.41M 20.44% | 407.8M 17.38% | |
| EBITDA YoY % growth | 22.773M -62.09% | -72.335M -417.63% | -42.405M 41.38% | -17.34M 59.11% | 5.1M 129.41% | 18.36M 260.00% | 26.932M 46.69% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | 1.747M -42.76% | -80.51M -4,708.47% | -42.78M 46.86% | -46.656M -9.06% | -23.856M 48.87% | -8.948M 62.49% | 65.994M 837.53% | 108.12M 63.83% | 151.47M 40.09% | 195.94M 29.36% | 241.64M 23.32% | |
| Operating Margin | 0.98% | -460.03% | -86.04% | -122.71% | -43.46% | -11.60% | 37.73% | 46.80% | 52.51% | 56.40% | 59.25% | |
| EPS YoY % growth | -1.29 52.75% | -1.01 21.71% | -0.73 27.72% | -0.53 27.90% | -0.31 41.09% | -0.17 45.72% | 0.52 409.09% | 0.85 62.75% | 1.18 39.76% | 1.53 29.31% | 1.88 22.67% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.09 43.47% | -0.10 46.73% | -0.10 13.30% | -0.08 68.34% | -0.06 38.54% | -0.07 27.66% |
| Revenue Q2Q % growth | 6.728M -32.87% | 9.782M -0.25% | 8.16M -7.61% | 9.078M 9.93% | 10.098M 50.09% | 11.424M 16.79% |
| EBITDA Q2Q % growth | -6.732M 46.77% | -7.038M 35.21% | -6.834M 32.99% | -6.018M 24.15% | -2.958M 56.06% | -1.122M 84.06% |
| EBIT Q2Q % growth | -9.713M 24.83% | -10.022M 10.82% | -3.468M 66.30% | -408K 94.98% | 100.00% | 2.958M 129.52% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
20.95%
EPS Next 5 Year
25.87%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
13.00%
Revenue Next 5 Year
34.00%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
33.43%
EBIT Next 5 Year
26.37%
RVL PHARMACEUTICALS PLC / RVLP Forecast FAQ
Can you provide the upcoming earnings date for RVL PHARMACEUTICALS PLC?
RVL PHARMACEUTICALS PLC (RVLP) will report earnings on 2023-11-08, before the market open.
What are the consensus estimates for RVLP stock next earnings?
The consensus EPS estimate for the next earnings of RVL PHARMACEUTICALS PLC (RVLP) is -0.09 USD and the consensus revenue estimate is 6.73M USD.
What is the consensus rating for RVL PHARMACEUTICALS PLC (RVLP) stock?
The consensus rating for RVL PHARMACEUTICALS PLC (RVLP) is 82.2222 / 100 . This indicates that analysts generally have a positive outlook on the stock.